Infertility

Ivy Fertility Hires Dr. Bryn Willson and Dr. Shelun Tsai

Retrieved on: 
Thursday, March 21, 2024
Baby, Maternity, Managed Care, Other Health, Health, Women, Other Science, Research, Hospitals, Genetics, Consumer, Science, Cedars-Sinai Medical Center, Education, Weill Cornell Medicine, SDFC, Patient, Duke University, UC, University, Weill Cornell Medical Center, MD, Pacific coast, Infertility, Gynaecology, Harvard University, University of California, Davis, Santa Clara University, Golden apple, Obstetrics, Duke, Physician, Hedera

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, is thrilled to welcome Bryn Willson, MD and Shelun Tsai, MD to its collaborative team of physicians.

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, is thrilled to welcome Bryn Willson, MD and Shelun Tsai, MD to its collaborative team of physicians.
  • Dr. Willson and Dr. Tsai are both board-certified in obstetrics and gynecology, and will complete their fellowships in reproductive endocrinology this spring.
  • “The entire Ivy Fertility network is committed to staying at the forefront of fertility science,” said Sandy Chuan, MD, Medical Director at San Diego Fertility Center.
  • “We are privileged that Dr. Willson and Dr. Tsai will be contributing their innovation and compassion to our network.”

Merck Foundation CEO, Senator Dr. Rasha Kelej Awarded on International Women’s Day for Her Efforts Towards Women Empowerment and Supporting Girl Education

Retrieved on: 
Friday, March 15, 2024
Other Education, University, Practice Management, Education, Business, Training, Professional Services, General Health, Philanthropy, Women, Children, Foundation, Other Philanthropy, Consumer, Health, Communication, Infertility, Woman, International, Art, Ministry, Social, Multimedia, Movement, Ambassador, Pharmaceutical industry

On the occasion of International Women’s Day, Business Executive Group awarded Senator Dr. Rasha Kelej, CEO of Merck Foundation , at their Global She Achievers Awards 2024, for her efforts to empower women in STEM, and girls in education, and building healthcare capacity in Africa and beyond.

Key Points: 
  • On the occasion of International Women’s Day, Business Executive Group awarded Senator Dr. Rasha Kelej, CEO of Merck Foundation , at their Global She Achievers Awards 2024, for her efforts to empower women in STEM, and girls in education, and building healthcare capacity in Africa and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240315990515/en/
    Senator Dr. Rasha Kelej, CEO of Merck Foundation (Photo: Business Wire)
    Senator Dr. Rasha Kelej, CEO of Merck Foundation expressed gratitude, remarking, "Firstly, Happy International Women’s Day to all the women in the world and to the men who support and empower them.
  • "It is a great honor to receive The Global She Achievers Award 2024, that too on the very important occasion of International Women’s Day.
  • Merck Foundation is contributing to building and advancing fertility care capacity in Africa and Asia, to support childless women and couples.

Reproductive Medicine Associates Opens New State-of-the-Art Fertility Center and IVF Lab in Bellevue, Expanding Access to Fertility Care in Washington State

Retrieved on: 
Wednesday, March 13, 2024
Science, Practice Management, Research, Managed Care, General Health, Health, Hospitals, Other Health, Seattle metropolitan area, Infertility, FACOG, Patient, IVF, Interstate 405, Reproductive medicine, Fertility, IUI, MD, IVI, RMA, Medical director, Interstate Highway System, PGT, MSCE, Birth control

Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.

Key Points: 
  • Reproductive Medicine Associates (RMA), one of the nation's leading reproductive service providers and a pioneer in IVF research, announced the opening of its new state-of-the-art fertility center and in vitro fertilization lab (IVF) in Bellevue.
  • The clinic is RMA’s second location in Washington state, after Seattle, and adds to an extensive network of more than sixty RMA clinics across the United States.
  • “We’re committed to expanding access to cutting-edge fertility care for the roughly 1 in 5 Americans who struggle with infertility,” said Lynn Mason, CEO of IVI RMA America.
  • The center will also offer family planning resources and options for LGBTQ+ individuals and fertility preservation treatments for those individuals with autoimmune diseases or cancer diagnoses.

Coast Guard Mutual Assistance (CGMA) and WIN Join Forces to Support Coast Guard Families in Their Family-Building Journey

Retrieved on: 
Wednesday, April 3, 2024
TRICARE, RET, Infertility, Partnership, WIN, Female, Fertility, Coast guard, Woman, USCG, CGMA, Coast Guard Mutual Assistance, Family, Birth control

GREENWICH, Conn., April 3, 2024 /PRNewswire/ -- WIN, the nation's leading family-building and family well-being benefit company, is proud to announce its collaboration with Coast Guard Mutual Assistance (CGMA) to provide comprehensive fertility benefit management services for Coast Guard members. The donated services offered include 24/7 clinical guidance through WIN Nurse Care Advocates, reproductive behavioral support, access to the WIN highly credentialed qualified network of medical and pharmacy providers and on-demand clinical support and resources through the WINFamily app—wherever their duties take them, along with available discounts, and guided counseling on family-building options.

Key Points: 
  • The CGMA-WIN initiative seeks to address these challenges by offering comprehensive support tailored to the needs of Coast Guard service members and their families.
  • "We understand the challenges that military families face and are committed to supporting Coast Guard members on their journey to parenthood.
  • Through this partnership, we aim to provide comprehensive and accessible resources that empower Coast Guard families to build their families."
  • "We are thrilled to offer WIN's support to our Coast Guard community's family-building aspirations," said RADM Cari B. Thomas, USCG (Ret), CEO of Coast Guard Mutual Assistance.

Family Source Consultants Celebrates Michigan Legislature Passing Landmark Fertility Health Care Act (House Bill 5207) to Legalize Surrogacy Arrangements

Retrieved on: 
Wednesday, March 27, 2024
Michigan Legislature, Infertility, Child, Fertility, Family, Organization, House, Woman, Heart, Consultant, Dream, Reproductive rights, Parent, Legislation, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Family Source Consultants Celebrates Michigan Legislature Passing Landmark Fertility Health Care Act (House Bill 5207) to Legalize Surrogacy Arrangements.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Family Source Consultants Celebrates Michigan Legislature Passing Landmark Fertility Health Care Act (House Bill 5207) to Legalize Surrogacy Arrangements.
  • Family Source Consultants, a leading third-party reproduction agency that specializes in matching and facilitating surrogacy and egg donation arrangements, praises the Michigan Legislature for taking a historic step forward in reproductive rights by passing the Fertility Health Care Act ( House Bill 5207 ).
  • This groundbreaking legislation legalizes and regulates surrogacy arrangements in the state of Michigan providing transparency and protection for all parties involved in a surrogacy arrangement.
  • By providing a legal framework for surrogacy, the Fertility Health Care Act aims to promote fairness, transparency, and ethical practices within the surrogacy process.

Renowned Los Angeles Urologist Dr. Justin Houman Appointed Assistant Professor at Cedars-Sinai Medical Center

Retrieved on: 
Wednesday, March 20, 2024
Diagnosis, Peyronie's disease, Health, Infertility, Prostate cancer, Assistant, Knowledge, Research, Fertility, Patient, Suite, Male, Cedars-Sinai Medical Center, Publication, Urinary tract infection, Erectile dysfunction, LOS, Kidney, Assistant professor

LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist, as Assistant Professor in the esteemed Department of Urology. With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.

Key Points: 
  • Dr. Justin Houman, M.D., brings expertise in clinical care, research, and medical education to Cedars-Sinai's Department of Urology.
  • LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist , as Assistant Professor in the esteemed Department of Urology.
  • With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.
  • In his role as Assistant Professor, Dr. Houman will impart invaluable knowledge and mentorship to medical students, residents, and fellows in urology.

Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

Retrieved on: 
Friday, March 15, 2024
Diagnosis, Uncertainty, Histology, Growth, Infertility, Cyst, Disease, University, Pelvis, Endometrioma, Patient, Rectum, Abdomen, Laparoscopy, Endometriosis, Society, Integrin, Woman, SRI, Pain, University of Oxford, FDA, Medical imaging

The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.

Key Points: 
  • The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.
  • Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford added: "Endometriosis is a common disease affecting many millions of women worldwide with pain and infertility.
  • Therefore, a novel imaging tool to assist healthcare professionals in identifying or ruling out the disease is urgently needed."
  • At the Endometriosis CaRe Centre at the University of Oxford our studies focus on identifying novel genetic, diagnostic and therapeutic targets for endometriosis.

Alife Health Partners with Boston IVF on AI Technology for IVF Treatment Optimization

Retrieved on: 
Tuesday, March 12, 2024
Algorithm, Infertility, Stim, Partnership, SAN, Patient, IVF, Research, AI, Machine learning, Reproductive medicine, Medical device

SAN FRANCISCO and BOSTON, March 12, 2024 /PRNewswire/ -- Alife Health ("Alife"), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), has announced a groundbreaking partnership with Boston IVF, a leading fertility clinic with more than 25 locations across the U.S., to pilot the country's first AI tool for IVF medication optimization. Boston IVF will implement Alife's Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.

Key Points: 
  • SAN FRANCISCO and BOSTON, March 12, 2024 /PRNewswire/ -- Alife Health ("Alife"), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), has announced a groundbreaking partnership with Boston IVF , a leading fertility clinic with more than 25 locations across the U.S., to pilot the country's first AI tool for IVF medication optimization.
  • Boston IVF will implement Alife's Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.
  • The collaboration aims to advance the field of reproductive medicine by combining Alife's state-of-the-art AI technology with the expertise of Boston IVF's world-renowned fertility specialists.
  • "Our partnership with Alife marks a major milestone in the advancement of AI technology for fertility treatment," says David Stern, CEO of Boston IVF.

Paralyzed Veterans of America issues statement in response to VA's expansion of IVF

Retrieved on: 
Monday, March 11, 2024
PVA, Disability, Fertilisation, IVF, Family, Congress, Marital status, Infertility, Birth control

WASHINGTON, March 11, 2024 /PRNewswire/ -- Paralyzed Veterans of America Chief Executive Officer Carl Blake issues the following statement in response to the Department of Veterans Affairs' expansion of in vitro fertilization for disabled veterans seeking to grow their families.

Key Points: 
  • WASHINGTON, March 11, 2024 /PRNewswire/ -- Paralyzed Veterans of America Chief Executive Officer Carl Blake issues the following statement in response to the Department of Veterans Affairs' expansion of in vitro fertilization for disabled veterans seeking to grow their families.
  • "PVA has long supported increased access to assisted reproductive technologies, including in vitro fertilization, through VA for catastrophically disabled veterans to grow their families.
  • Blake continued, "While VA's announcement is a tremendous step forward, more advancements are still needed.
  • PVA has long called on Congress to authorize VA to provide assisted reproductive technology, including IVF, surrogacy, and gamete donation at VA for any veterans enrolled in VA health care.

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Retrieved on: 
Wednesday, March 6, 2024
FDA, ICSI, IVF, Supreme Court of Alabama, Woman, Infertility, Female, Fertilisation, Patient, Tubing (recreation)

ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces the first commercial procedure using its FemaSeed intratubal insemination product.

Key Points: 
  • “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court.
  • Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
  • Dr. Andrew Wagner, Women’s OB-GYN PC, Saginaw, Michigan, who completed the first in-office commercial procedure, stated, “This marks a pivotal moment for women pursuing a reliable, readily available frontline alternative for infertility.